Palvella Therapeutics计划于2026年下半年向FDA提交新药申请

美股速递
Feb 24

生物制药公司Palvella Therapeutics Inc (PVLA) 近日公布了其关键药物的最新进展。根据公司规划,Palvella预计将在2026年下半年向美国食品药品监督管理局(FDA)正式提交新药申请(NDA)。这一时间表的公布,标志着该公司核心研发项目进入了重要的冲刺阶段,为后续的商业化进程奠定了基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10